Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daquan Wang

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Journal of the National Cancer Center|July 22, 2024
The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapyTao Zhang, Jianyang Wang, Daquan Wang, et al.
Eclinicalmedicine|April 18, 2025
Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trialShiyang Zheng, Shouliang Ding, Biaoshui Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 10, 2021
Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP modelXinLei Ai, Bo Qiu, Yin Zhou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2023
Patlak-Ki derived from ultra-high sensitivity dynamic total body [<sup>18</sup>F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patientsDaQuan Wang, Bo Qiu, QianWen Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|May 16, 2021
Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized TrialBo Qiu, QiWen Li, JunLing Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)NaiBin Chen, QiWen Li, SiYu Wang, et al.
Radiation Oncology (London, England)|June 15, 2019
Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective studyDaquan Wang, Nan Bi, Tao Zhang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 8, 2021
A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancerTao Zhang, Wenji Xue, Daquan Wang, et al.
Signal Transduction and Targeted Therapy|September 28, 2025
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trialBo Qiu, Yuanyuan Zhao, Wenzhuo He, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Journal of the National Cancer Center|July 22, 2024
The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapyTao Zhang, Jianyang Wang, Daquan Wang, et al.
Eclinicalmedicine|April 18, 2025
Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trialShiyang Zheng, Shouliang Ding, Biaoshui Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 10, 2021
Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP modelXinLei Ai, Bo Qiu, Yin Zhou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2023
Patlak-Ki derived from ultra-high sensitivity dynamic total body [<sup>18</sup>F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patientsDaQuan Wang, Bo Qiu, QianWen Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|May 16, 2021
Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized TrialBo Qiu, QiWen Li, JunLing Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)NaiBin Chen, QiWen Li, SiYu Wang, et al.
Radiation Oncology (London, England)|June 15, 2019
Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective studyDaquan Wang, Nan Bi, Tao Zhang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 8, 2021
A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancerTao Zhang, Wenji Xue, Daquan Wang, et al.
Signal Transduction and Targeted Therapy|September 28, 2025
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trialBo Qiu, Yuanyuan Zhao, Wenzhuo He, et al.
Pageof 9